Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
The company expects sales of its core ELISA kits, raw materials for in vitro diagnostic products and human-type collagen to increase, while also expecting foreign exchange rates and tariffs, raw-material costs, logistics costs, utility costs and labor costs to rise.
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥1,087 million（+8.2%） |
| Operating profit | Not disclosed → ¥322 million（+14.5%） |
| Ordinary income | Not disclosed → ¥322 million（+7.1%） |
| Profit attributable to owners of the parent | Not disclosed → ¥347 million（+5.5%） |
| Net income per share | Not disclosed → 37.26 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Fiscal year ended March 2026 results: revenue of ¥1,004 million, operating profit of ¥281 million, ordinary profit of ¥300 million, profit attributable to owners of the parent of ¥329 million, and earnings per share of ¥35.33 |
| Reason for the revision | The company expects sales of its core ELISA kits, raw materials for in vitro diagnostic products and human-type collagen to increase, while also expecting foreign exchange rates and tariffs, raw-material costs, logistics costs, utility costs and labor costs to rise. |
| Dividend forecast revision | The annual dividend for the fiscal year ending March 2027 is expected to be ¥7.50, comprising ¥0.00 at the end of the second quarter and ¥7.50 at the end of the fiscal year. The annual dividend for the fiscal year ended March 2026 was ¥6.00. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, results benefited from the continued adoption of ELISA kits by overseas CRO companies, increased sales of raw-material antibodies for in vitro diagnostic products, contract services and NeoSilk® human-type collagen I, higher sales of high-margin products, and tighter cost management. For the fiscal year ending March 2027, the company expects sales of ELISA kits, raw materials for in vitro diagnostic products and human-type collagen to increase, while identifying foreign exchange rates and tariffs, raw-material costs, logistics costs, utility costs and labor costs as risks.